N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer. Superficial bladder ...

TUR is both diagnostic and therapeutic, and findings or outcomes can dictate further disease management. Restaging TUR in patients with T1 tumors is an important component of management. Intravesical ...

“You have cancer.” Few words carry more weight. For people diagnosed with non–muscle invasive bladder cancer (NMIBC), advances in the field can be encouraging; yet, even amid innovation and ongoing ...

Therapeutic options to treat intermediate-risk and BCG-unresponsive bladder cancer, such as medications and ablative therapies, are expanding, and novel PET tracers enable improved diagnosis and ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...